Treatment for basal cell carcinoma

Abstract

The present invention provides a method of treating basal cell carcinoma in a subject. Generally, the method includes administering to the subject an amount of IRM compound effective for treating basal cell carcinoma in a treatment cycle that includes at least two consecutive days in which the IRM compound is administered and at least one day in which the IRM compound is not administered.

1 . A method of treating basal cell carcinoma in a subject, the method comprising administering to the subject an amount of an IRM compound effective for treating basal cell carcinoma, wherein the IRM compound is administered in a treatment cycle that comprises at least two consecutive days in which the IRM compound is administered and at least one day in which the IRM compound is not administered. 
   
   
       2 . The method of  claim 1  wherein the treatment cycle comprises at least five days in which the IRM compound is administered. 
   
   
       3 . The method of  claim 2  wherein the treatment comprises at least five consecutive days in which the IRM compound is administered. 
   
   
       4 . The method of  claim 1  wherein the treatment cycle comprises at least two consecutive days in which the IRM compound is not administered. 
   
   
       5 . The method of  claim 1  wherein the treatment cycle comprises five days in which the IRM compound is administered and at least two days in which the IRM compound is not administered. 
   
   
       6 . The method of  claim 5  wherein the five days are five consecutive days. 
   
   
       7 . The method of  claim 1  wherein the method comprises at least two treatment cycles. 
   
   
       8 . The method of  claim 7  wherein the method comprises at least six treatment cycles. 
   
   
       9 . The method of  claim 1  wherein administering the IRM compound comprises applying one dose of the IRM compound per day. 
   
   
       10 . The method of  claim 1  wherein administering the IRM compound comprises topically applying the IRM compound to a treatment area that includes a lesion. 
   
   
       11 . The method of  claim 10  wherein the IRM compound is applied in a formulation that comprises from about 1% to about 10% IRM compound. 
   
   
       12 . The method of  claim 11  wherein the formulation comprises about 5% IRM compound. 
   
   
       13 . The method of  claim 11  wherein the formulation is applied to the treatment area for from about two hours to about 24 hours. 
   
   
       14 . The method of  claim 13  wherein the formulation is applied to the treatment area for from about six hours to about twelve hours. 
   
   
       15 . The method of  claim 11  wherein the formulation is applied to the treatment area for about eight hours. 
   
   
       16 . The method of  claim 10  wherein the treatment area further comprises skin at least 0.5 cm beyond the margin of the lesion.